Bernard Combe

43.9k total citations · 4 hit papers
481 papers, 14.3k citations indexed

About

Bernard Combe is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Bernard Combe has authored 481 papers receiving a total of 14.3k indexed citations (citations by other indexed papers that have themselves been cited), including 386 papers in Rheumatology, 136 papers in Hematology and 125 papers in Immunology. Recurrent topics in Bernard Combe's work include Rheumatoid Arthritis Research and Therapies (335 papers), Systemic Lupus Erythematosus Research (142 papers) and Autoimmune and Inflammatory Disorders Research (112 papers). Bernard Combe is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (335 papers), Systemic Lupus Erythematosus Research (142 papers) and Autoimmune and Inflammatory Disorders Research (112 papers). Bernard Combe collaborates with scholars based in France, United States and Netherlands. Bernard Combe's co-authors include Jacques Morel, J Sany, Jean Sibilia, Cédric Lukas, Maxime Dougados, C. Hua, Alain Cantagrel, Thomas Barnetche, Philippe Goupille and Xavier Mariette and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Immunology.

In The Last Decade

Bernard Combe

452 papers receiving 13.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

2006 566 citations Bernard Combe, Cédric Lukas et al. Annals of the Rheumatic Diseases profile →
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study

2008 465 citations Désirée van der Heijde, Robert Landewé et al. profile →
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

2018 331 citations Mark C. Genovese, Bernard Combe et al. profile →
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

2021 163 citations Bernard Combe, Alan Kivitz et al. Annals of the Rheumatic Diseases profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Bernard Combe	10.1k	3.7k	3.3k	2.0k	1.8k	481	14.3k
E. William St. Clair	9.1k 0.9×	3.2k 0.9×	5.3k 1.6×	2.3k 1.2×	1.7k 0.9×	170	16.5k
Larry W. Moreland	12.2k 1.2×	5.0k 1.3×	4.7k 1.4×	2.4k 1.2×	2.3k 1.3×	291	18.9k
Daniel Aletaha	15.0k 1.5×	5.4k 1.4×	4.7k 1.4×	2.4k 1.2×	2.4k 1.3×	327	21.2k
Arthur Kavanaugh	7.6k 0.8×	3.5k 0.9×	4.1k 1.3×	1.5k 0.8×	1.2k 0.7×	195	11.4k
Kimme L Hyrich	7.6k 0.8×	3.8k 1.0×	3.2k 1.0×	1.6k 0.8×	1.3k 0.7×	313	12.2k
Joachim R. Kalden	8.4k 0.8×	3.5k 0.9×	4.4k 1.3×	1.5k 0.7×	1.3k 0.7×	163	13.4k
Gianfranco Ferraccioli	6.0k 0.6×	1.7k 0.5×	2.7k 0.8×	1.6k 0.8×	2.1k 1.2×	370	11.5k
Stanley Cohen	10.5k 1.0×	4.7k 1.3×	4.5k 1.4×	2.3k 1.2×	1.8k 1.0×	214	18.4k
Vibeke Strand	15.4k 1.5×	5.6k 1.5×	6.3k 1.9×	2.0k 1.0×	2.6k 1.4×	522	22.9k
Tatsuya Atsumi	9.5k 0.9×	5.0k 1.3×	4.2k 1.3×	719 0.4×	1.2k 0.7×	512	15.5k

Countries citing papers authored by Bernard Combe

Since Specialization

Citations

This map shows the geographic impact of Bernard Combe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Combe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Combe more than expected).

Fields of papers citing papers by Bernard Combe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Combe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Combe. The network helps show where Bernard Combe may publish in the future.

Co-authorship network of co-authors of Bernard Combe

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard Combe. A scholar is included among the top collaborators of Bernard Combe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard Combe. Bernard Combe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Avouac, Jérôme, et al.. (2025). The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations. Rheumatology and Therapy. 12(2). 211–236. 2 indexed citations

Buch, Maya H, Daniel Aletaha, Bernard Combe, et al.. (2024). Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study. RMD Open. 10(4). e004476–e004476. 1 indexed citations

Moltó, Anna, Sandrine Alonso, Francis Bérenbaum, et al.. (2024). Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort. RMD Open. 10(3). e004484–e004484. 1 indexed citations

Tanaka, Yoshiya, Tsutomu Takeuchi, Tatsuya Atsumi, et al.. (2023). Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses. Rheumatology and Therapy. 10(6). 1399–1415. 2 indexed citations

Buch, Maya H, Bernard Combe, José A. Gómez‐Puerta, et al.. (2023). OA06 Clinical outcomes of filgotinib in patients with rheumatoid arthritis aged ≥65 years: a post hoc subgroup analysis of Phase 2 and 3 clinical trials and ongoing long-term extensions. Lara D. Veeken. 62(Supplement_2). 1 indexed citations

Dougados, Maxime, Sandrine Alonso, Francis Bérenbaum, et al.. (2023). Ten-year clinical outcome of recent-onset axial spondyloarthritis: Results from the DESIR inception Cohort. Joint Bone Spine. 91(3). 105678–105678. 4 indexed citations

Heijde, Désirée van der, Atul Deodhar, Walter P. Maksymowych, et al.. (2022). Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open. 8(2). e002280–e002280. 32 indexed citations

Sellam, Jérémie, E. Maheu, M.D. Crema, et al.. (2021). The DIGICOD cohort: A hospital-based observational prospective cohort of patients with hand osteoarthritis – methodology and baseline characteristics of the population. Joint Bone Spine. 88(4). 105171–105171. 22 indexed citations

Combe, Bernard, Alan Kivitz, Yoshiya Tanaka, et al.. (2021). Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Annals of the Rheumatic Diseases. 80(7). 848–858. 163 indexed citations breakdown →

10.

Behrens, Frank, Soyi Liu Leage, Christophe Sapin, et al.. (2021). Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52. Clinical Rheumatology. 40(12). 4943–4954. 1 indexed citations

11.

Landewé, Robert, Pedro Machado, Féline P B Kroon, et al.. (2020). EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Annals of the Rheumatic Diseases. 79(7). 851–858. 153 indexed citations

12.

Hua, C., Frank Buttgereit, & Bernard Combe. (2020). Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open. 6(1). e000536–e000536. 104 indexed citations

13.

Dejaco, Christian, Alessia Alunno, J. W. J. Bijlsma, et al.. (2020). Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. Annals of the Rheumatic Diseases. 80(4). 518–526. 51 indexed citations

14.

Gottenberg, Jacques‐Eric, Jacques Morel, Élodie Perrodeau, et al.. (2019). Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ. 364. l67–l67. 93 indexed citations

15.

Daïen, C., C. Hua, C. Gaujoux-Viala, et al.. (2018). Actualisation des Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. Revue du Rhumatisme. 86(1). 8–24. 6 indexed citations

16.

Cailar, Guilhem du, Rachel Audo, Cédric Lukas, et al.. (2017). Sodium excretion is higher in patients with rheumatoid arthritis than in matched controls. PLoS ONE. 12(10). e0186157–e0186157. 17 indexed citations

17.

Maksymowych, Walter P., Robert Landewé, Joan M. Bathon, et al.. (2012). Validation of Prognostic Biomarkers for RA: Testing of 14-3-3 Eta According to the Omeract Soluble Biomarker Criteria. Data Archiving and Networked Services (DANS). 2 indexed citations

18.

Meyer, Olivier, Michel De Bandt, Jean‐Marie Berthelot, et al.. (2006). Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6months' first-line DMARD therapy. Joint Bone Spine. 74(1). 73–78. 14 indexed citations

19.

Coudeyre, Emmanuel, et al.. (2003). Traduction française et adaptation culturelle du « back book »French translation and cultural adaptation of the “back book”. University of Huddersfield Repository (University of Huddersfield). 1 indexed citations

20.

Reginster, Jean‐Yves, et al.. (1993). Evaluation of efficacy and safety of oral tiludronate in Paget's disease of bone: a double-blind, dose-ranging, placebo-controlled study. Open Repository and Bibliography (University of Liège). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact